Up to 10% of patients with locally advanced rectal cancer will experience locoregional recurrence. In the setting of prior surgery and often radiation and chemotherapy, these represent uniquely challenging cases. When feasible, surgical resection offers the best chance for oncologic control yet risks significant morbidity. Studies have consistently indicated that a negative surgical resection margin is the strongest predictor of oncologic outcomes. Chemoradiation is often recommended to increase the chance of an R0 resection, and in cases of close/positive margins, intraoperative radiation/brachytherapy can be utilized. In patients who are not surgical candidates, radiation can provide symptomatic relief. Ongoing phase III trials are aiming to address questions regarding the role of reirradiation and induction multiagent chemotherapy regimens in this population.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- phase iii
- phase ii study
- open label
- clinical trial
- minimally invasive
- radiation induced
- squamous cell carcinoma
- radiation therapy
- type diabetes
- prostate cancer
- coronary artery bypass
- double blind
- risk assessment
- acute coronary syndrome
- free survival
- case control
- skeletal muscle
- glycemic control